Stock Watch: Brace For European Biotech Departures From NASDAQ
Waning Investor Appetite And Cost Cutting May Drive Biotechs Home
A NASDAQ listing has been the pinnacle for non-US biotech companies because it brings access to more specialist investors and a larger capital base. But the appetite for – and aftermarket performance of – this biotech tourism is cycle-dependent.
You may also be interested in...
When a small biotech company acquires a failed drug from big pharma and plans to repeat the clinical studies expecting a positive result, is that not a definition of insanity?
Key to the deal is investment by German billionaire Dietmar Hopps; GPC, troubled since satraplatin failed to meet trial endpoints, gains Agennix’s NCSLC candidate, talactoferrin.
Biotech CEOs often express surprise when the FDA rejects their drugs. But collaborative interactions between regulators and drug sponsors count for little if the latter fail to adjust their clinical and regulatory efforts accordingly.